Seeking Alpha

BridgeBio: Post Attruby Approval, Shares Don't Look Such Good Value - Rating Downgrade

BridgeBio's lead drug Attruby's approved for ATTR-CM last November has driven a 40% stock increase; however, competition and market dynamics may limit its near-term revenue potential. Despite ...
STAT

BridgeBio wins FDA approval for heart disease drug

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. The Food and Drug ...
Nasdaq

BridgeBio Pharma Reports Strong Early Demand for Attruby and Updates on Phase 3 Clinical Trials

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...
STAT

Sales of BridgeBio’s new heart drug blow past expectations

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. BridgeBio’s recently ...

Immutrin raises $87M to advance drug for progressive heart disease

The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, “ATTR-CM,” that has become a ...
Nasdaq

BridgeBio announces FDA approved Attruby for ATTR-CM patients

BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults ...
Insider Monkey

UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby ...
Seeking Alpha

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

-Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of ...

How The BridgeBio Pharma (BBIO) Narrative Is Shifting With Attruby And Late Stage Pipeline

BridgeBio Pharma is back in focus after its fair value estimate was lifted from $89.79 to $100.05, an increase of about 11% that resets the conversation around upside and risk. That move aligns with ...

Morgan Freeman brings awareness to ATTR-cardiac amyloidosis (ATTR-CM)

Award-winning actor Morgan Freeman has a presence that can command a room without stepping into it. On and off screen, his ...
Wall Street Journal

A Short Lesson in Drug Competition

Whoever says the Food and Drug Administration is too cozy with Big Pharma isn’t paying attention to the bonanza of new treatments launched by biotech startups. Late last week the FDA approved ...